Alan E Mast

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8971594/publications.pdf

Version: 2024-02-01

87 papers	4,036 citations	126907 33 h-index	123424 61 g-index
90 all docs	90 docs citations	90 times ranked	3655 citing authors

#	Article	IF	Citations
1	Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clinical Chemistry, 1998, 44, 45-51.	3.2	391
2	A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. ELife, 2020, 9, .	6.0	296
3	Biology of tissue factor pathway inhibitor. Blood, 2014, 123, 2934-2943.	1.4	235
4	Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood, 2002, 99, 1489-1491.	1.4	200
5	Iron deficiency in blood donors: the REDSâ€‖ Donor Iron Status Evaluation (RISE) study. Transfusion, 2012, 52, 702-711.	1.6	184
6	Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. Blood Advances, 2017, 1, 1132-1141.	5.2	164
7	Iron deficiency in blood donors: analysis of enrollment data from the REDSâ€‖ Donor Iron Status Evaluation (RISE) study. Transfusion, 2011, 51, 511-522.	1.6	161
8	Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17838-17843.	7.1	137
9	Tissue Factor Pathway Inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 9-14.	2.4	136
10	Oral Iron Supplementation After Blood Donation. JAMA - Journal of the American Medical Association, 2015, 313, 575.	7.4	133
11	Reticulocyte hemoglobin content. American Journal of Hematology, 2008, 83, 307-310.	4.1	114
12	Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood, 2007, 109, 1931-1937.	1.4	113
13	Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3927-3931.	7.1	74
14	Demographic correlates of low hemoglobin deferral among prospective whole blood donors. Transfusion, 2010, 50, 1794-1802.	1.6	63
15	Behavioral, biochemical, and genetic analysis of iron metabolism in highâ€intensity blood donors. Transfusion, 2008, 48, 2197-2204.	1.6	62
16	Restless legs syndrome, pica, and iron status in blood donors. Transfusion, 2013, 53, 1645-1652.	1.6	59
17	The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores. Transfusion, 2012, 52, 1031-1040.	1.6	57
18	Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfusion and Apheresis Science, 2008, 38, 9-14.	1.0	51

#	Article	IF	Citations
19	Characterization of the Association of Tissue Factor Pathway Inhibitor With Human Placenta. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 2099-2104.	2.4	48
20	Effect of iron supplementation on iron stores and total body iron after whole blood donation. Transfusion, 2016, 56, 2005-2012.	1.6	48
21	A randomized, blinded, placeboâ€controlled trial of education and iron supplementation for mitigation of iron deficiency in regular blood donors. Transfusion, 2016, 56, 1588-1597.	1.6	48
22	Intradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDSâ€III RBCâ€Omics study. Transfusion, 2019, 59, 79-88.	1.6	47
23	SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung. ELife, 2021, 10, .	6.0	46
24	Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood, 2010, 116, 1787-1794.	1.4	45
25	Murine Hematopoietic Cell Tissue Factor Pathway Inhibitor Limits Thrombus Growth. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 821-826.	2.4	44
26	Frequent blood donations alter susceptibility of red blood cells to storageâ€and stressâ€induced hemolysis. Transfusion, 2019, 59, 67-78.	1.6	44
27	Blood, sweat, and tears: Red Blood Cellâ€Omics study objectives, design, and recruitment activities. Transfusion, 2019, 59, 46-56.	1.6	44
28	Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. Journal of Clinical Investigation, 2021, 131, .	8.2	42
29	Alternatively spliced isoforms of tissue factor pathway inhibitor. Thrombosis Research, 2010, 125, S52-S56.	1.7	41
30	Protein S Is a Cofactor for Platelet and Endothelial Tissue Factor Pathway Inhibitor-Î± but Not for Cell Surfaceâ€“Associated Tissue Factor Pathway Inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 169-176.	2.4	41
31	Elevated risk for iron depletion in highâ€school age blood donors. Transfusion, 2019, 59, 1706-1716.	1.6	39
32	Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochemical Journal, 2002, 367, 451-458.	3.7	38
33	Targeting TFPI for hemophilia treatment. Thrombosis Research, 2016, 141, S28-S30.	1.7	38
34	Laboratory variables for assessing iron deficiency in <scp>REDSâ€I</scp>ron <scp>S</scp>tatus <scp>E</scp>valuation (<scp>RISE</scp>) blood donors. Transfusion, 2013, 53, 2766-2775.	1.6	36
35	Contribution of Regions Distal to Glycine-160 to the Anticoagulant Activity of Tissue Factor Pathway Inhibitor. Biochemistry, 2002, 41, 4989-4997.	2.5	35
36	Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 93-104.	2.3	33

#	Article	IF	Citations
37	Tissue Factor Pathway Inhibitor Binds to Platelet Thrombospondin-1. Journal of Biological Chemistry, 2000, 275, 31715-31721.	3.4	32
38	Low hemoglobin deferral in blood donors. Transfusion Medicine Reviews, 2014, 28, 18-22.	2.0	32
39	TFPIÎ± interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation. Blood Advances, 2017, 1, 2692-2702.	5.2	31
40	Development and evaluation of a transfusion medicine genome wide genotyping array. Transfusion, 2019, 59, 101-111.	1.6	30
41	Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight, 2022, 7, .	5.0	29
42	Blood center practice and education for blood donors with anemia. Transfusion, 2011, 51, 929-936.	1.6	23
43	The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation*. British Journal of Haematology, 2012, 156, 388-401.	2.5	22
44	Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica, 2013, 98, 1324-1330.	3.5	21
45	2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. Transfusion, 2017, 57, 1568-1581.	1.6	20
46	Iron status and risk factors for iron depletion in a racially/ethnically diverse blood donor population. Transfusion, 2019, 59, 3146-3156.	1.6	20
47	FcRn augments induction of tissue factor activity by IgG-containing immune complexes. Blood, 2020, 135, 2085-2093.	1.4	19
48	Intersection of regulatory pathways controlling hemostasis and hemochorial placentation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	19
49	Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. Journal of Thrombosis and Haemostasis, 2022, 20, 1290-1300.	3.8	19
50	Estimates of total body iron indicate 19 mg and 38 mg oral iron are equivalent for the mitigation of iron deficiency in individuals experiencing repeated phlebotomy. American Journal of Hematology, 2017, 92, 851-857.	4.1	18
51	The benefits of iron supplementation following blood donation vary with baseline iron status. American Journal of Hematology, 2020, 95, 784-791.	4.1	18
52	A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. Blood, 2015, 125, 4078-4084.	1.4	17
53	Teenage Blood Donors: Are We Asking Too Little and Taking Too Much?. Pediatrics, 2017, 139, .	2.1	17
54	Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state. Blood Advances, 2017, 1, 386-395.	5.2	17

#	Article	IF	Citations
55	Populationâ€based screening for anemia using firstâ€time blood donors. American Journal of Hematology, 2012, 87, 496-502.	4.1	14
56	The operational implications of donor behaviors following enrollment in STRIDE (Strategies to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	1.6	14
57	Suppressive Role of Tissue Factor Pathway Inhibitor-Î± in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength. Thrombosis and Haemostasis, 2018, 118, 502-513.	3.4	14
58	Caveolae optimize tissue factorâ€“Factor VIIa inhibitory activity of cell-surface-associated tissue factor pathway inhibitor. Biochemical Journal, 2012, 443, 259-266.	3.7	12
59	Qualitative assessment of pica experienced by frequent blood donors. Transfusion, 2017, 57, 946-951.	1.6	12
60	The price of blood is measured in iron. Lancet, The, 2017, 390, 2331-2333.	13.7	11
61	Translation of Human Tissue Factor Pathway Inhibitor-Î² mRNA Is Controlled by Alternative Splicing Within the 5â€² Untranslated Region. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 187-195.	2.4	10
62	Tissue factor pathway inhibitor is required for cerebrovascular development in mice. Blood, 2021, 137, 258-268.	1.4	10
63	Major Reservoir for Heparin-Releasable TFPIÎ± (Tissue Factor Pathway Inhibitor Î±) Is Extracellular Matrix. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1942-1955.	2.4	10
64	Community blood donors' knowledge of anemia and design of a literacyâ€appropriate educational intervention. Transfusion, 2010, 50, 75-79.	1.6	9
65	Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency. Blood Advances, 2019, 3, 489-498.	5.2	9
66	Genetic and behavioral modification of hemoglobin and iron status among firstâ€time and highâ€intensity blood donors. Transfusion, 2020, 60, 747-758.	1.6	9
67	Demographic, clinical, and biochemical predictors of pica in a large cohort of blood donors. Transfusion, 2021, 61, 2090-2098.	1.6	9
68	Sex hormone intake in female blood donors: impact on haemolysis during cold storage and regulation of erythrocyte calcium influx by progesterone. Blood Transfusion, 2019, 17, 263-273.	0.4	9
69	The health implications of low hemoglobin deferral in infrequent blood donors. Transfusion, 2015, 55, 86-90.	1.6	8
70	Putting donor health first in strategies to mitigate donor iron deficiency. Transfusion, 2017, 57, 495-498.	1.6	8
71	Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia. Haemophilia, 2019, 25, 1083-1091.	2.1	8
72	Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery. Thrombosis and Haemostasis, 2018, 118, 1545-1555.	3.4	7

#	Article	IF	Citations
73	Red blood cell transfusion does not increase risk of venous or arterial thrombosis during hospitalization. American Journal of Hematology, 2021, 96, 218-225.	4.1	7
74	CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models. Journal of Thrombosis and Haemostasis, 2021, 19, 1932-1947.	3.8	7
75	Factor V east Texas variant causes bleeding in a threeâ€generation family. Journal of Thrombosis and Haemostasis, 2022, 20, 565-573.	3.8	7
76	Iron status and selfâ€reported fatigue in blood donors. Transfusion, 2021, 61, 124-133.	1.6	5
77	Association of proton pump inhibitor and histamine H2-receptor antagonists with restless legs syndrome. Sleep, 2021, 44, .	1.1	5
78	Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. British Journal of Haematology, 2016, 175, 123-132.	2.5	4
79	Alternatively spliced tissue factor pathway inhibitor: Functional Implications. Frontiers in Bioscience - Scholar, 2011, S3, 1457.	2.1	4
80	Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell. Journal of Thrombosis and Haemostasis, 2020, 18, 2083-2086.	3.8	3
81	Intrauterine lethality in Tfpi gene disrupted mice is differentially suppressed during midâ€and lateâ€gestation by platelet TFPIÎ± overexpression. Journal of Thrombosis and Haemostasis, 2021, 19, 1483-1492.	3.8	3
82	The contribution of TFPIÎ± to the hemostatic response to injury in mice. Journal of Thrombosis and Haemostasis, 2021, 19, 2182-2192.	3.8	3
83	Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis. BMC Genomics, 2022, 23, 227.	2.8	2
84	Demographic, clinical, and biochemical predictors of pica in highâ€intensity blood donors. Transfusion Medicine, 2022, 32, 288-292.	1.1	2
85	Response to comment on â€˜SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lungâ€™. ELife, 2022, 11, .	6.0	1
86	Reducing Iron Deficiency in Teen-Aged Blood Donors. Pediatrics, 2020, 146, .	2.1	0
87	Relieving Inhibition of Prothrombinase By TFPIÎ±: a Procoagulant Activity of Unfractionated, Low Molecular Weight, and Nonanticoagulant Heparins. Blood, 2014, 124, 1478-1478.	1.4	0